Clinical Trials Logo

Clinical Trial Summary

Type II diabetes is a known risk factor for heart failure, particularly through the progressive development of diabetic cardiomyopathy. Cardiac metabolic parameters, including myocardial steatosis and epicardial fat, are altered in diabetic patients. The development of new anti-diabetics (incretins) has demonstrated protective cardiovascular effects independent of effects on glycemic control for the first time in the history of these therapies. Thus Glucagon-Like Peptide 1 (GLP-1) agonists improve the recovery of cardiac function after a heart attack and decrease atheromatous processes. It has also been demonstrated in a diabetic rat model that the administration of Liraglutide, a GLP-1 agonist, leads to normalization of myocardial steatosis associated with beneficial cardiac molecular remodeling involving pro-apoptotic, oxidative and metabolic processes. These beneficial cardiovascular effects were observed in the absence of any changes in blood glucose, insulin levels or body weight.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03498001
Study type Interventional
Source Centre Hospitalier Universitaire Dijon
Contact
Status Recruiting
Phase N/A
Start date April 16, 2018
Completion date December 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03463941 - Peer Support Dyads in Churches N/A
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Active, not recruiting NCT02586129 - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes Phase 3
Completed NCT01698528 - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration N/A
Completed NCT00985114 - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity N/A
Active, not recruiting NCT02914743 - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes N/A
Completed NCT02429258 - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin Phase 4
Completed NCT01055223 - Fracture Risk With Thiazolidinediones N/A
Terminated NCT02365233 - Fatty Liver Study in Patients With Type II Diabetes Phase 4
Terminated NCT01804777 - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes Early Phase 1
Completed NCT01619332 - Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Phase 1/Phase 2
Completed NCT01881074 - Periodontal Treatment Response in Type II Diabetic Patients
Not yet recruiting NCT01591525 - Diabetes Mellitus Community Based Screening in Minority Populations N/A
Recruiting NCT00694278 - Clinical Evaluation of the Effect of Duodenal-Jejunal Bypass on Type 2 Diabetes Phase 0
Completed NCT00882882 - To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions Phase 1
Unknown status NCT02637609 - Measuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst Scaling N/A
Unknown status NCT02637622 - Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment N/A
Recruiting NCT02974699 - Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans Early Phase 1
Active, not recruiting NCT03024788 - Determination of the Optimum Cut-off Value of Type 2 Diabetes Diagnosis Among Chinese Population(SENSIBLE STUDY II) N/A
Active, not recruiting NCT02673762 - Salivary Transcriptome Biomarkers for Early Diabetes Detection